The present disclosure is directed to isolated recombinant antibodies, or antigen-binding fragments thereof, that bind to fentanyl or fentanyl analogs. The novel antibodies or antigen-binding fragments thereof can be used to detect, diagnose, treat, and/or prevent opioid use disorder.

The present disclosure is directed to isolated recombinant antibodies, or antigen-binding fragments thereof, that bind to fentanyl or fentanyl analogs. The novel antibodies or antigen-binding fragments thereof can be used to detect, diagnose, treat, and/or prevent opioid use disorder.

Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein -------, R.sup.1, R.sup.2, R.sup.5, A and L are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and/or anesthesia. ##STR00001##

A method of treating a patient suffering from low back by administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of an antibody that binds specifically to nerve growth factor (NGF) or an antigen binding fragment thereof.

Neuropeptide FF receptor modulators based on a proline scaffold are provided which offer NPFF receptor potencies in the nanomolar range and antagonistic selectivity for the NPFF1 receptor. Methods, compounds and compositions for modulating the function of neuropeptide FF receptors are provided for pharmacotherapies capable of influencing conditions or disorders affected by the neuropeptide FF receptors.

Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and/or reduction of side effects attributable to opioid use.

Compounds and methods for modulating the activity of receptors are disclosed. Some of the compounds modulate the activity of glycine receptors. Certain embodiments of the compounds are useful for treatment of pain, treatment of opioid addiction, and/or reduction of side effects attributable to opioid use.

Described is the preparation of novel fentanyl haptens of Formula (1) through (6) and their use in the preparation of effective fentanyl vaccines.

Described is the preparation of novel fentanyl haptens of Formula (1) through (6) and their use in the preparation of effective fentanyl vaccines.

The present invention provides a composition which comprises a compound which is a mixture of deuterium containing and non-deuterium containing molecules having the structure:

##STR00001## wherein R.sub.1 is

##STR00002## wherein at least one of H.sub.1, H.sub.2 or H.sub.3 is a deuterium-enriched —H site, or

##STR00003## wherein at least one of H.sub.1, H.sub.2, H.sub.3, H.sub.4 or H.sub.5 is a deuterium-enriched —H site,
or a pharmaceutically acceptable salt of the compound, and methods of using the composition to treat pain, depressive disorders, mood disorders, anxiety disorders, opioid use disorders, and opioid withdrawal symptoms.